Hillary’s vaccine price plan didn’t work the first time for a reason

by is licensed under
The zombie scheme to control drug costs by having the government set prices is back from the dead.

Pundits in Forbes, The New Yorker and the Huffington Post have been raging about the “unsustainable” price of new cancer drugs all year. But anger about drug prices really went viral when Martin Shkreli, the CEO of Turing Pharmaceuticals, hiked the price of a generic tuberculosis drug he acquired by 5,000 percent.

Now price-control proposals are on the ballot in California, Ohio, Massachusetts and other states. Unsurprisingly, such plans are supported and encouraged by Hillary Rodham Clinton, who warned she’d rein in prices.

Biotechnology stocks fell: Investors remembered what happened the last time Clinton went on a price-control mission.

But not everyone does. To refresh:

As first lady and in charge of the Bill Clinton administration’s health-care reform effort, Hillary accused “greedy” drug companies of exorbitant price increases for vaccines. In 1993, she first proposed nationalizing the vaccine industry. She settled for a Vaccines for Children Program that saw the federal government buy up over half of all available vaccines at government-set prices.
Article Photo Credit: by is licensed under
Sign Up for Our Email Newsletter

RECENT NEWS

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

New JCI Viewpoint: FDA Must Rethink How It Evaluates Precision Medicines for Rare Diseases

Authors argue that rare disease innovation requires learning more from fewer patients—not enrolling more patients...  Read more

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Troubling Trends: Systemic Practices in Texas' Non-Profit Hospitals That Inflate Health Care Costs

Texas has an opportunity to lead rather than react. Better measurement would strengthen public confidence without diminis...  Read more

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

PROTECTING THE U.S. PHARMACEUTICAL SUPPLY CHAIN: A PATH FORWARD

How proactive FDA policies can help strengthen the American pharmaceutical supply chain of essential medicines, create jo...  Read more

DRUGWONKS BLOG